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Available online 21 December 2012Abstract Vascular injury and destruction of endothelial cells (ECs) are the early events in scleroderma (SSc) patients. This study
aims to investigate the therapeutic potential of human-induced pluripotent stem cell-derived ECs (hiPSC-ECs) to treat SSc. We have
assessed the functional differentiation of hiPSC-ECs and compared themwith human embryonic stem cell-derived ECs (hESC-ECs) by a
variety of in vitro experimental approaches. Additionally, we evaluated the therapeutic potential of hiPSC-ECs in a bleomycin-induced
SSc mouse model. Our results demonstrated that hiPSC-ECs and hESC-ECs showed similar maximum expressions of FLK1 (early EC
marker) at day five during differentiation. After sorting and culturing, the FLK1-positive cells exhibited spindle and subsequent
endothelial cobblestone morphology in EGM2 medium. The hESC-ECs and hiPSC-ECs also expressed late EC markers CD31 (68% and
75%), CD144 (50% and 61%), CD146 (46% and 61%), and DiI-labeled acetylated low-density lipoprotein (DiI-ac-LDL) uptake (55% and
63%), respectively. They additionally formed capillary-like structures on Matrigel. Analyses of the transplantation of sorted
CD31-positive hiPSC-ECs into the bleomycin-induced SSc mouse model demonstrated that these cells participate in recovery of the
damaged vessels. Therewas a reduction in collagen content; the number of total and degranulatedmast cells returned to their normal
state, and bleomycin-inducedwounds aswell as skin fibrosis improved fourweeks after transplantation of hiPSC-ECs. Our findings have
shown that the differentiation process from hESCs and hiPSCs to vascular cell components is similar. Additionally, this is the first study
to determine the therapeutic potential of vascular cells from hiPSCs in the treatment of an SSc model. In the future, with further
validation, these may be used as an appropriate source for the treatment of SSc patients.
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289Therapeutic effect of hiPSC-EC in scleroderma modelIntroductionScleroderma (systemic sclerosis, SSc) is a connective tissue
disease characterized by vascular injury, the excessive
accumulation of extracellular matrix (ECM) proteins in the
skin and various internal organs, and immunological abnor-
malities (Yamamoto, 2009). SSc is resistant to all types of
treatments (Yamamoto, 2009). Endothelial cells (ECs) are
affected in the early stages of SSc (Gabrielli et al., 2009;
Kahaleh, 2008). In early lesions there are changes of
the endothelial phenotype or EC apoptosis in the absence
of EC proliferation or precursor differentiation (Gabrielli
et al., 2009; Kahaleh, 2008). It has been reported that
mesenchymal stem cells (MSCs) and endothelial progen-
itor cells (EPCs) from SSc patients show abnormalities in
differentiation to ECs (Cipriani et al., 2007; Trojanowska,
2010). Recently, clinical improvement in patients with SSc
has been demonstrated following administration of high
dose immunosuppressive therapy and autologous hemato-
poietic cell transplantation (Fleming et al., 2008). Addition-
ally, it has been demonstrated that isolated EPCs from
normal peripheral blood participate and increase the for-
mation of new blood vessels (Asahara et al., 1999; Isner
et al., 2001). However, isolation of EPCs from adults has
limited replicative capacity. In elderly patients with cardio-
vascular risk factors, EPCs are few in number and dysfunc-
tional (Heeschen et al., 2004; Hill et al., 2003; Vasa et al.,
2001). The discovery of human embryonic stem (hESCs)
(Thomson et al., 1998) and human-induced pluripotent stem
cells (hiPSCs) (Takahashi et al., 2007; Yu et al., 2007), due to
their capacities for self-renewal and pluripotency, have
provided fascinating possibilities and hopes for curing
diseases that have poor prognoses. Until now, several
reports have described the differentiation and functionality
of ECs derived from murine (Kim and von Recum, 2009; Li
et al., 2007; Sone et al., 2003; Yamashita et al., 2000),
primate (Kaufman et al., 2004; Sone et al., 2003), and
human (Levenberg et al., 2002; Li et al., 2011) ESCs or iPSCs
(Li et al., 2011; Rufaihah et al., 2011). The beneficial
influences of hESC-derived ECs (hESC-ECs) in the setting of
myocardial or limb ischemia has been reported (James
et al., 2010; Kane et al., 2010; Levenberg et al., 2002, 2010;
Li et al., 2009; Nourse et al., 2010; Rufaihah et al., 2010;
Sone et al., 2007). Transplantation of hiPSC-ECs also
enhanced capillary density and improved reperfusion in a
limb ischemia mouse model (Rufaihah et al., 2011). However,
no study has yet reported the therapeutic potential of
hESC-ECs or hiPSC-ECs in the treatment of damaged vessels
that result from SSc.
Therefore, in this report, initially we induced hESCs
and hiPSCs into mesodermal FLK1-positive cells. Subse-
quently, these positive cells were sorted and differenti-
ated into ECs. Considering the characterization of these
differentiated cells and comparing their functionality,
we have concluded that hiPSCs can efficiently differen-
tiate into ECs in a manner similar to hESCs. Finally, we
have evaluated the therapeutic potential of transplanted
hiPSC-ECs into a bleomycin-induced SSc mouse model
and investigated the synthesis of TGF-β1, total and de-
granulated mast cell numbers, and collagen content
alternation.Materials and methods
Antibodies
Monoclonal antibodies for human FLK1 (1:100, GR8507-2)
were purchased from Abcam. Monoclonal antibodies for
human CD31 (1:200, 555444), CD144 (1:200, 555661), CD146
(1:200, 550314), vWF (1:200, 555849), and CD45 (1:200,
345808) for immunostaining and flow cytometry were
obtained from Beckton Dickenson (BD). Secondary murine
polyclonal antibodies IgG1-FITC (1:200, 04611) and IgG1-PE
(1:200, 340270) were purchased from BD.
hESCs and hiPSCs culture and EC differentiation
hESCs (Royan H5, 46XX) and hiPSCs (hiPSC1, 46XY, derived
from a healthy 40-year-old Iranian male) were obtained from
the Stem Cell Bank at Royan Institute (Baharvand et al., 2006;
Totonchi et al., 2010) and cultured feeder-free on Matrigel
(1:30, Sigma-Aldrich, E1270)-coated cell culture dishes in
DMEM-F12 (Gibco-Invitrogen, 21331-020, USA) supplemented
with 10% knockout serum replacement (KOSR, Gibco-
Invitrogen, 10828-028), 2 mM L-glutamine (Gibco-Invitrogen,
25030-024), 0.1 mM2-mercaptoethanol (Sigma-Aldrich, M7522,
USA), 1% nonessential amino acids (NEAAs, Gibco-Invitrogen,
11140-035), 100 IU/ml penicillin, 100 mg/ml streptomycin
(Gibco-Invitrogen, 15070-063), insulin-transferrin-selenite
(ITS, Gibco-Invitrogen, 41400-045), and 100 ng/ml basic
fibroblast growth factor (bFGF, Royan Institute). hESCs and
hiPSCs were induced to differentiate as described previously
(Levenberg et al., 2010). Briefly, 5–6×104 hESCs or hiPSCs
were cultured for six days on type-IV collagen-coated dishes
(0.5 mg/ml, Sigma-Aldrich, C5533) in α-MEM medium
(Gibco-Invitrogen, 22571) supplemented with 10% fetal bovine
serum (FBS, Gibco-Invitrogen, 10270106), 1% NEAAs, and 1%
penicillin/streptomycin. The cells were dissociated with colla-
genase (1 mg/ml, Gibco-Invitrogen, 17104-019) and dispase
(2 mg/ml, Gibco-Invitrogen, 17105-041) for 10 min. FLK1-
positive sorted cells were subcultured on collagen type I
(8 μg/cm2, Sigma-Aldrich, C3867) with EGM-2 medium (Lonza,
CC-3162) until confluency.
Human umbilical vein endothelial cell isolation
and culture
Umbilical cords from newborn infants were washed with
phosphate buffered saline (PBS, Gibco-Invitrogen, 21600-069)
to remove internal blood. Then, veins were filled with
collagenase IV (0.1%, 1 mg/ml) and incubated at 37 °C for
10 min. After collecting the cell suspensions and centrifuging
at 4 °C and 1500 rpm, cell pellets were cultured in M-199
medium (Gibco-Invitrogen, 31100-027) supplemented with
10% FBS, 1% NEAA, and 1% penicillin/streptomycin.
Flow cytometry and cell sorting
After induction of FLK1-positive cells on collagen IV andα-MEM
medium, at differentiation day 5, cells were dissociated with
trypsin/EDTA (Gibco-Invitrogen, 15400-054). Following neu-
tralization with α-MEM supplemented with 10% FBS, cells were
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quently, cells were allowed to incubate for 1 h at 4 °C with
mouse IgG1 monoclonal anti-human FLK-1 and then washed
with FACS buffer. Secondary polyclonal rat anti-mouse
IgG1-PE or FITC was added and cells incubated for 1 h at
4 °C. After washing with FACS buffer, FLK1-positive cells were
sorted by FACS Calibur (USA). This method was also used for
sorting CD31-positive cells in EGM-2 medium. After differen-
tiation of FLK1-positive cells into ECs in EGM-2 medium, the
cells were dissociated using trypsin/EDTA after reaching
confluency. Afterwards, cells were fixed with 4% paraformal-
dehyde (Sigma-Aldrich, P6148) and stained with monoclonal
antibodies for CD31, CD144, CD146, FLK1, and CD45. Cells
were washed twice with PBS before being subjected to flow
cytometry analysis (FACS Aria, USA).Immunostaining
Cells were fixed in 4% paraformaldehyde, blocked by 1% rat
serum (Royan Institute), and incubated overnightwith primary
antibodies at 4 °C. Anti-mouse IgG antibodies conjugatedwith
PE or FITC were used as secondary antibodies. Nuclei were
stained with DAPI (1:1000 Sigma-Aldrich, D-8417). After each
incubation, cells were washed twice with PBS. Stained cells
were photographed with fluorescence microscopy (BX51;
Olympus; Japan). To quantify the numbers of hESC-ECs and
hiPSC-ECs, positively stained cells were counted in 12 random-
ly selected fields. Each experiment was repeated at least
three times, with 3–4 slides each time, and approximately
2000 cells totally were counted.Colony-forming assay
Endothelial cell colony-forming units (CFU-ECs) were cultured
using the EndoCult Liquid Medium Kit (Stem Cell Technologies,
05901-2, Vancouver, BC, Canada) as per the manufacturer's
protocol. FLK1-positive sorted cells were resuspended in
complete EndoCult medium and seeded at 10–15×103 cells/
well on fibronectin (Sigma-Aldrich, F-0635)-coated tissue
culture plates. Cells were incubated at 37 °C and 5% CO2 for
21 days. The cells were supplementedwith new growth media
four days after plating. At 7, 14, and 21 days after plating the
numbers of CFU-ECs were counted in a minimum of three
wells. A colony was defined as a central cluster of round cells
with spindle-shaped cells that radiated from the periphery
(Hill et al., 2003).Uptake of acetylated low-density
lipoprotein (DiI-ac-LDL)
Acetylated low-density lipoprotein (DiI-ac-LDL; Biomedical
Technologies Inc., MA) was diluted to 10 μg/ml in complete
growth medium and added to the cells and the mixture was
allowed to incubate for 4 h at 37 °C. Then, we removed the
medium and washed the cells with probe-free media. Cells
were fixed with 4% paraformaldehyde. The nuclei were
stained with 4, 6-diamidino-2-phenylindole (DPAI, 1:1000
Sigma-Aldrich, D-8417) and finally visualized with fluores-
cence microscopy.Tube formation by ECs in vitro
ECs were cultured to form tubes in vitro as described pre-
viously (Balconi et al., 2000). Briefly, Matrigel matrix was
diluted to 0.5–0.7 mg/ml in endothelial differentiation
medium. ECs that were differentiated for five passages were
trypsinized and replated at 3–5×104 cells in 300 μl of 0.5–
0.7 mg/ml Matrigel onto each well of the 12-well plates. The
Matrigel-cell suspension was polymerized for 2–4 h at 37 °C.
Again, 300 μl of endothelial differentiation medium was
added by semi-depletion to the dish and cells were incubated
at 37 °C and 5% CO2. The structures were photographed under
phase contrast microscope (Olympus, IX71).
Scleroderma mouse model and
hiPSC-EC transplantation
All animal care, surgical processes and post-operative eutha-
nasia were undertaken in strict accordance with the approval
of the Institutional Review Board and Institutional Ethical
Committee at Royan Institute. All efforts were made to
minimize the number of animals used. The SSc animal model
was induced in six-week old female BALB/C mice (Pasteur
Institute, Tehran, Iran) by daily subcutaneous injections of
bleomycin (100 μg/ml, Merck, 46520202) for 4 weeks as
previously described (Yamamoto, 2010). Additionally, cell-
recipient mice were injected with cyclosporine solution
(SandImmune; Novartis Pharmaceuticals, Switzerland) intra-
peritoneally at a dose of 20 mg/kg/24 h.
Then, hiPSC-ECs (1×106 cells in 100 μl of culture media;
n=7–8 mice/group) were injected subcutaneously in three
equidistant sites of the sclerotic skin. Control SSc mice were
injected only with bleomycin (100 μg/ml) for 4 weeks. To
study differentiated EC tracing, we labeled the cells with
fluorescent DiI dye (Cell Tracker CM-DiI, Invitrogen Molecular
Probes, 697948). Before transplantation, cells in the suspen-
sion were washed with PBS and incubated with DiI at a
concentration of 2.5 μg/ml PBS for 5 min at 37 °C and 15 min
at 4 °C. After two washing steps in PBS, the cells were
resuspended in EGM-2 medium.
Histopathology and immunohistochemistry
The dorsal skin of the neck was removed after the final
injection at one and four weeks post-transplantation. The skin
pieces were fixed in 10% formalin solution and embedded in
paraffin. Six micrometer-thick paraffin sections were pre-
pared on poly L-lysine-coated slides. The sections were
counterstained with Masson's trichrome (MT) stain, dehy-
drated, cleared, and mounted. Dermal thickness was mea-
sured after taking photographs under a light microscope of the
MT stained sections and quantified by Image J software
version 1.4. To evaluate the fate of labeled transplanted cells
at 1 and 4 weeks post-transplantation, slides were stained
with anti-vWF antibody. Briefly, sections were simultaneously
blocked in serum and permeabilized with 0.2% Triton X-100
for 30 min at 37 °C. The primary antibody (1:200, mouse
anti-human vWF) was diluted in blocking solution and sections
were incubated overnight at room temperature. Secondary
antibody (1:200, rat anti-mouse IgG-FITC) was applied for 1 h
at 37 °C followed by washing with PBS. All washes consisted of
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were counterstained with DAPI and sections visualized using a
fluorescence microscope (Olympus BX51; Japan). At each
stage, control sections were incubated with blocking serum
without antibody to confirm antibody specificity.
Mast cell number
Mast cells were identified by toluidine blue staining. Cells that
containedmetachromatic granules were counted in 12 random
fields under light microscope power field magnifications of 4×,
10×, and 100×. A total of 7–8mice per group and 5–6 slides per
mouse were used for counting total mast and degranulated
cells.
Enzyme-linked immunosorbent assay of serum cytokine
Sera were obtained by cardiac puncture at two and four weeks
of treatment with bleomycin (n=6) and from transplanted
mice at four weeks after transplantation (n=7). Sera were
stored at −80 °C. Serum levels of TGF-β1 were assed using an
enzyme-linked immunosorbent assay (ELISA) kit (R&D System).Figure 1 Differentiation of hESCs and hiPSCs into endothelial cells
hESCs and hiPSCs to endothelial cells (ECs) and transplantation into
Col: collagen. (B) Phase-contrast images show similar EC differentia
IV-coated dishes. (C) Flow cytometric analysis of hESCs and hiPSCs-d
maximum expression on day 5 during differentiation (*Pb0.05).Statistical analysis
We used one-way ANOVA to compare the differences between
independent groups as well as Levene's test for homogeneity
of variance and the Kolmogorov–Smirnov for test of normality.
Two-way analysis of variance (ANOVA) was used to consider
the simultaneous effect of two variables on outcome and the
Kruskal–Wallis test compared the differences between inde-
pendent groups' samples. We used repeated measures ANOVA
followed by the Tukey post hoc test. Multiple group compar-
ison was used to analyze group differences of the resultant
data. Data were expressed as mean±SD. P≤0.05 was con-
sidered significant.
Results
Differentiation of hESCs and hiPSCs to ECs
The experimental scheme for hESCs and hiPSCs differentia-
tion into ECs (CD31-positive cells) and their transplantation
used in this study is illustrated in Fig. 1A. Initially, the(ECs). (A) Schematic representation of the differentiation from
a scleroderma (SSc) mouse model. S: stage, D: day, P: passage,
tion and growth characteristics of hESCs and hiPSCs on collagen
erived FLK1-positive cells on collagen IV-coated dishes revealed
292 M. Azhdari et al.undifferentiated hESCs and hiPSCs were maintained in
feeder-free conditions on Matrigel with DMEM-F12 medium.
To induce differentiation, hESCs and hiPSCs were replated as
small clusters on collagen IV-coated dishes in α-MEM medium
and 10% FBS. Under these conditions, outgrown cells
gradually changed their morphology from a circular mode
into spindle and subsequently cobblestone mode in EGM-2
medium (Fig. 1B). Temporal expression of the EPC marker(FLK1) (Yamashita et al., 2000) of differentiating cells by
flow cytometry showed that the proportion of FLK1-positive
cells peaked at day 5 of differentiation after culturing on
collagen IV-coated plates and in differentiation medium
(Fig. 1C).
FLK1-positive cells were sorted by FACS on day 5 of
differentiation and enriched to ~95% (Fig. 2A). The sorted
FLK1-positive cells had colony forming potential in
Figure 3 Histopathology of dermal sclerosis in mice. (A) Schematic illustration outlining the in vivo procedure comprising the study
period, time of injury, and transplantation in the scleroderma (SSc) mouse model by bleomycin administration. (B) The SSc model.
The gated pictures show the skin and lung of PBS- and BLM-treated mice. (C) Masson's trichrome (MT)-stained in normal, PBS- and
bleomycin-treated skin. Marked dermal scleroses with thickened and homogenous collagen bundles (right panel) were induced.
Arrows indicate increasing collagen amount and extension of the dermis. (D) Quantification of collagen content in normal, PBS- and
bleomycin-treated mice skin. Dermal thickness increased after bleomycin injection, but PBS-treated mice did not exhibit an increase
in dermal thickness. Significant differences were between bleomycin-treated mice with normal and PBS-treated mice (*Pb0.05).
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7 days after plating with the maximum colony count observed
on day 21 (Fig. 2C). There was no significant difference
between both cell lines in colony counts on the same days
after plating.
The sorted FLK1-positive cells were replated on a collagen
I-coated dish in endothelial growth medium (EGM2 medium in
the presence of its supplements). These FLK1-positive sortedFigure 2 Characterization of hESC- and hiPSC-derived FLK1-posit
hiPSCs increased after FACS. (B) CFU-EC colonies generated from
micrograph of a hiPSC-endothelial progenitor cell (hiPSC-EPC) colony
by radiating thin and flat cells. The first colony was observed after se
(data not shown). CFU: colony-forming unit. (C) Quantification of CF
were replated on collagen I in EGM-2 medium to generate ECs. These
“spindle” (early EPC) and “cobblestone-” (late EPC) like morphol
of hESC- and hiPSC-derived FLK1-positive cells after sorting at
(F) Immunofluorescence staining of hESC-ECs and hiPSC-ECs showed
images were observed from hESC-ECs (DiI-ac-LDL uptake in hESC-ECs
(blue). (G) Phase-contrast microscopic analysis showed that, simila
formed capillary-like structures after 14–21 days of differentiation.cells were successfully propagated for five passages with the
use of 0.025%–0.01% trypsin–EDTA every 7–10 days on
collagen I-coated dishes. These differentiated hESC-ECs and
hiPSC-ECs from sorted FLK1-positive cells formed a “cobble-
stone” monolayer (Fig. 2D), and immunofluorescence staining
revealed that these cells were positive for endothelial marker,
CD31 (PECAM1; Fig. 2E). Flow cytometric analyses showed that
differentiated hESC-ECs and hiPSC-ECs expressed endothelialive cells. (A) The purity of FLK1-positive cells from hESCs and
hiPSC-FLK1-positive cells in EndoCult medium. Phase-contrast
defined by a central cluster of rounded cells that is surrounded
ven days in culture. Similar colonies were observed in hESC-FLK1
U-ECs in hESC-ECs and hiPSC-ECs. (D) Sorted FLK1-positive cells
cells are shown at passage 5. FLK1-positive cells display typical
ogy in culture. (E) Flow cytometric analysis of differentiation
passage 5 during differentiation into ECs in EGM-2 medium.
expression of CD31 and DiI-ac-LDL uptake in hiPSC-ECs. Similar
is not shown). Nuclear counterstaining was performed with DAPI
r to HUVECs, hESC-ECs and hiPSC-ECs after plating on Matrigel
Data are presented as mean±SD.
294 M. Azhdari et al.markers CD31 (68% and 75%), CD144 (50% and 61%) and
CD146 (46% and 61%), respectively (Fig. 2F). EPC marker
(FLK1) was down-regulated to ~11%–13% in the derived ECs.
The cells were monocyte marker CD45 negative (1%–2%;
Fig. 2F).
Uptake of DiI-ac-LDL has been used to characterize ECs
(Voyta et al., 1984) and results showed that these differen-
tiated cells were able to incorporate DiI-ac-LDL (55% in
hESC-ECs and 63% in hiPSC-ECs), when cells were incubated
with this substance (Figs. 2E and F). In addition, whenFigure 4 Characterization of bleomycin-induced scleroderma mou
4 weeks of bleomycin treatment. Normal; PBS-treated; and bleomyci
sclerotic skin by toluidine blue staining at 4 weeks. Right panel shows h
mast cells was quantified by identification of toluidine blue staining a
mast cells show significant differences in bleomycin-treated mice in co
significant differences between PBS-treated and normal mice. (D) Se
bleomycin and PBS after the final application at weeks 2 and 4. Compar
mice show a significant increase in TGF-β1 during weeks 2 and 4 (Pb0hESC-ECs and hiPSC-ECs were plated on Matrigel, they formed
tube-like structures after 14–21 days (Fig. 2G).Induction of SSc animal model and transplantation
of hiPSC-ECs
We induced an SSc animal model by subcutaneous local
injection of bleomycin (Yamamoto, 2010) in BALB/C mice
(Figs. 3A and B). MT staining demonstrated intense depositionse model. (A) Mast cell infiltrates were prominent in the skin at
n-treated skin in mice. Metachromasy phenomenon was shown in
igher magnification. (B) The number of total and (C) degranulated
t weeks 1, 2, and 4 (mean±SD). Total number and degranulated
ntrast to PBS-treated and normal mice (**Pb0.01). There were no
rum TGF-β1 was measured by ELISA the day after application of
edwith PBS-treated or normal untreatedmice, bleomycin-treated
.05).
295Therapeutic effect of hiPSC-EC in scleroderma modelof type 1 collagen in the dermis after bleomycin treatment
when compared with PBS-treated mice (Fig. 3C). Cutaneous
fibrosis was also quantified by analysis of collagen content.
Results showed that collagen content in the punch-biopsied
skins increased up to three-fold by bleomycin treatment
compared to those treated with PBS (Fig. 3D).
As observed with toluidine blue staining, mast cells
increased in numbers in parallel with the induction of SSc
(Figs. 4A and B). Marked degranulation was noted, and
compared with PBS-treated mice (Fig. 4C). Assessment withFigure 5 Isolation and expansion of hiPSC-ECs. (A) The quantificat
hiPSCs-derived endothelial cells (ECs) after sorting using CD31 antib
lines at the same experiments. (B) Fluorescence microscopy images
The red color in the cytoplasm represents DiI-ac-LDL. (C) Phase-contr
on a collagen I-coated dish. (D) Isolated human umbilical vein ECs (HELISA showed that the TGF-β1 serum level in bleomycin-
treated mice was significantly higher than those of PBS-
treated mice (Fig. 4D).
Before transplantation, hiPSC-ECs were sorted for the CD31
marker. After sorting, flow cytometry analyses showed that
~95% of the cells were CD31-positive (Fig. 5A). These cells
expressed high levels of vWF (83%) and had rapid uptake of
DiI-ac-LDL (93%; Figs. 5A and B). The cells also formed an in
vitro “cobblestone” monolayer on a collagen I-coated dish
(Fig. 5C). hESC-ECs also exhibited similar results after sortingion of CD31, vWF expression, and DiI-ac-LDL uptake in hESCs and
ody. There were no significant differences between the two cell
from CD31, vWF expression, and DiI-ac-LDL uptake in hiPSC-ECs.
ast microscopic analysis of recultured CD31-positive sorted cells
UVECs) were used as the positive control.
296 M. Azhdari et al.(Fig. 5). Isolated human umbilical vein ECs (HUVECs) were
used as the positive control (Fig. 5D).
Next, we transplanted CD31-purified positive cells that
were derived from hiPSCs into the mice model. For tracing
transplanted cells, we used DiI labeling. According to fluo-
rescence microscopy images one week after transplantation,
DiI-labeled hiPSC-ECs localized robustly at the injection site
of the skin (Fig. 6A). However, four weeks after transplanta-
tion these labeled cells were distributed in skin tissue along
with cell division (data not shown) and homed around vessels,
particularly the distracted micro vessels (Fig. 6A). These DiI-
positive cells were positive for human vWF antigen (Fig. 6C).
Quantitative analysis of MT staining of tissue sections, one
and four weeks post-transplantation, showed significant
reduction in collagen deposition in the hiPSC-EC transplanted
group four weeks post-transplantation compared to the
control group (Fig. 7).
There were decreased counts in the numbers of total and
degranulated mast cells four weeks post-transplantation
(Figs. 8A–C), but the serum levels of TGF-β1 did not
significantly change after cell transplantation when com-
pared with the control group (Fig. 8D).Discussion
Endothelium destruction and loss of ECs are the main events
in SSc patients. To date, few cell therapy studies have been
performed for SSc.Figure 6 Transplantation of DiI-labeled hiPSC-ECs into the sclero
EGM-2) were subcutaneously transplanted into bleomycin-induced d
after transplantation shows that: (i) hiPSC-ECs are present in skin t
(iii) the merge of DiI and vWF-positive cells. (B) (i) hiPSC-ECs in skin
DiI-labeled hiPSC-ECs around micro vessels. The magnification was in
antigen after four weeks. Merge of DiI and vWF-positive cells is showIn this study, we described the differentiation of hiPSCs
into efficient functional ECs and compared them with
hESC-ECs. We have found that hiPSCs, similar to hESCs, can
be differentiated into ECs by the use of a sequential com-
bination of FLK1-positive (EPCmarker) and CD31-positive (late
EC marker) sorting. These ECs show typical endothelial
cobblestone morphology, express lineage specific markers
(CD31, CD144, and CD146), and can take up DiI-ac-LDL as well
as form endothelial tubes on Matrigel. These results are in
agreement with other recent reports on the differentiation
and functionality of ESC and iPSC-derived ECs (Kaufman et al.,
2004; Kim and von Recum, 2009; Levenberg et al., 2002; Li
et al., 2007, 2011; Rufaihah et al., 2011; Sone et al., 2003;
Yamashita et al., 2000).
We induced SSc in a mouse model by administering daily
subcutaneous injections of bleomycin. The model was charac-
terized by accumulation of collagen bundles, increased mast
cell numbers (particularly in the edematous phase), observa-
tion of degranulated mast cells, and the release of TGF-β1 as
previously noted (Jinnin et al., 2004; Li et al., 2007; Reinecke
and Murry, 2002; Yamamoto, 2010). We observed that trans-
planted hiPSC-ECs showed homing around damaged vessels,
with improvements in collagen deposition, the numbers of total
and degranulated mast cells, in addition to superficial injury
healing four weeks post-transplantation. The beneficial effects
of hESC-ECs and hiPSC-ECs in the setting of myocardial or limb
ischemia have also been reported (James et al., 2010; Kane
et al., 2010; Levenberg et al., 2002, 2010; Li et al., 2009;
Nourse et al., 2010; Rufaihah et al., 2010; Sone et al., 2007).derma (SSc) mouse model. DiI-labeled hiPSC-ECs (1×106/100 μl
orsal neck skin. (A) Assessment of labeled cells homing one week
issue; (ii) labeled cells are positive for human vWF antigen; and
tissue four weeks after transplantation. (ii), (iii) and (iv) show
creased from (i) to (iv). (C) Homed cells positive for human vWF
n.
Figure 7 Photomicrographs of scleroderma mouse skin sections after hiPSC-EC transplantation. (A) hiPSC-EC transplanted mouse
four weeks after transplantation showed improvement. (B) hiPSC-EC transplanted mice, one week after transplantation showed
packed collagen fibers that extended from the epidermis to the underside muscle layer. The sections were stained with MT.
Transplanted hiPSC-EC group four weeks after transplantation showed decreased collagen content. Normal and control groups four
weeks after final bleomycin treatment. (C) Quantification of collagen content after transplantation. Collagen content one week after
transplantation in hiPSC-ECs and control groups shows significant difference with normal mice, whereas four weeks after
transplantation the hiPSC-EC group shows significant decreases in collagen content in contrast to the control group. (Both control and
hiPSC-EC groups were treated with bleomycin before transplantation. The control group was only injected with EGM2 medium on the
transplantation day. *Pb0.05.)
297Therapeutic effect of hiPSC-EC in scleroderma modelThe mechanism for this improvement remains to be
determined; however, it may be based on the following: (i)
attendance of a subpopulation of mature or precursor cells
that survive, migrate, and differentiate to ECs, (ii) paracrine
effects, and/or (iii) the prevention of mononuclear cell
infiltration, thus resulting in improvement of symptoms
(Fig. 9). We have observed the incorporation of hiPSC-ECs
into existing damaged vasculature.
Poor donor cell survival of transplanted hiPSC-ECs has been
reported in other studies as indicated by serial histology, the
Taqman Sry PCR technique, or TUNEL apoptosis assay (Li et
al., 2007; Reinecke and Murry, 2002). This may be related to
stimulation of the immune system of animals by human cells or
may be related to inappropriate receipt of a signal required
for efficient integration of hiPSC-ECs into mouse vasculature.
Alternatively, it is likely that the injected cells have a
paracrine effect. Recently, it has been demonstrated that
transplanted hiPSC-ECs in an ischemic limb model caused
secretion of the angiogenic cytokines and growth factors,
including angiopoietin-1, vascular endothelial growth factor-A
and -C, and platelet-derived growth factor-AA (Rufaihah
et al., 2011). However, additional studies are necessary to
test our hypothesis. In addition, the perivascular infiltration
of mononuclear cells (MNC) is associated with increased
collagen synthesis in adjacent fibroblasts (Jinnin et al., 2004).
Therefore hiPSC-EC transplantation, homing, and incorporationin the reconstruction of damaged vascular barriers can prevent
MSC infiltration, which will lead to the prevention of extra
collagen synthesis and subsequent occurrence of fibrosis by
intervening in the fibrotic process.
No evidence of tumor formation has been demonstrated
in the transplanted group. Therefore, although teratomas
are predominantly derived from the hiPSC graft, purified
pluripotent stem cell-ECs provide an opportunity for cell
therapy.
One of the limitations of our study is that we focused on one
hiPSC line; additional research on more hiPSC lines is
necessary. According to our results, as proven by previous
studies, there is a limitation in the expansion potential of
hiPSC-ECs when compared with hESC-ECs (Li et al., 2011).
Another limitation is cell labeling with DiI, and the use of
immunosuppressed mice which require more reliable cell
tracking, noninvasive cell tracking, and immunodeficient
mice. Furthermore, although autologous hiPSCs minimize
(Zhao et al., 2011) or possibly eliminate the need for immune
suppression after cell transplantation, however a number of
technical issues such as ‘epigenetic memory’ and karyotypic
instability during culture (Ji et al., 2010; Kim et al., 2010;
Lister et al., 2011; Marchetto et al., 2009; Polo et al., 2010)
need to be addressed before they are considered for clinical
applications. Some key advances aimed at overcoming these
safety concerns have been reached with the production of iPS
Figure 8 Assessment of mast cell numbers and serum TGF-β1 after hiPSC-EC transplantation. (A) Metachromasy phenomenon was
shown by toluidine blue staining. The control group received bleomycin for 4 weeks and PBS (or EGM-2 without cells) only on the
transplantation day. (B) Total mast cell and (C) degranulated mast cell number. Four weeks after transplantation, total and
degranulated mast cell numbers in the hiPSC-EC group reached the normal range. (D) Upregulation in serum TGF-β1 four weeks after
transplantation was observed in both control and cell transplanted groups in comparison with normal ones. *Pb0.05.
298 M. Azhdari et al.cells (for review see Gonzalez et al., 2011; Seifinejad et al.,
2010; Stadtfeld and Hochedlinger, 2010).
In conjunction, these early data have shown proof of
concept that transplantation of ECs derived from hiPSCs,
similar to hESC-ESc, can provide some benefits in the setting
for SSc regeneration. With further validation, the ECs that
are isolated from hESCs and hiPSCs, as described here, can
provide a continual endothelial cell source of therapy forFigure 9 A possible mechanism for scleroderma improvement by
cells into the existing damaged vasculature or by a paracrine effec
cells (MNCs) we could improve collagen deposition, reduce the numb
mouse model of SSc.vascular regeneration in SSc in addition to other diseases
with endothelial abnormalities.
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